MX9202243A - Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio. - Google Patents

Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.

Info

Publication number
MX9202243A
MX9202243A MX9202243A MX9202243A MX9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A MX 9202243 A MX9202243 A MX 9202243A
Authority
MX
Mexico
Prior art keywords
angiotensin
pharmaceutical composition
receptor antagonist
calcium channel
channel blockers
Prior art date
Application number
MX9202243A
Other languages
English (en)
Spanish (es)
Inventor
Pancras Chor Bun Wong
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of MX9202243A publication Critical patent/MX9202243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX9202243A 1991-05-15 1992-05-14 Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio. MX9202243A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15

Publications (1)

Publication Number Publication Date
MX9202243A true MX9202243A (es) 1992-11-01

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9202243A MX9202243A (es) 1991-05-15 1992-05-14 Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.

Country Status (11)

Country Link
EP (1) EP0584250A1 (enExample)
JP (1) JP2930252B2 (enExample)
AU (1) AU664375B2 (enExample)
CA (1) CA2103276A1 (enExample)
CZ (1) CZ281570B6 (enExample)
IE (1) IE921534A1 (enExample)
IL (1) IL101858A (enExample)
MX (1) MX9202243A (enExample)
NZ (1) NZ242724A (enExample)
WO (1) WO1992020342A1 (enExample)
ZA (1) ZA923557B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
WO1995026188A1 (en) * 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
US6245787B1 (en) 1995-03-16 2001-06-12 Pfizer Inc. Composition containing amlodipine or a pharmaceutically acceptable salt thereof, and an ACE inhibitor
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
PT1096932E (pt) 1998-07-10 2007-09-21 Novartis Pharma Ag ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio''
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PL377344A1 (pl) 2003-01-31 2006-01-23 Sankyo Company, Limited Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
DK0565634T3 (da) * 1990-12-14 1999-09-27 Smithkline Beecham Corp Angiotensin-II-receptorblokkersammensætninger

Also Published As

Publication number Publication date
CZ281570B6 (cs) 1996-11-13
IL101858A0 (en) 1992-12-30
JP2930252B2 (ja) 1999-08-03
IL101858A (en) 1996-08-04
CA2103276A1 (en) 1992-11-16
WO1992020342A1 (en) 1992-11-26
EP0584250A1 (en) 1994-03-02
AU664375B2 (en) 1995-11-16
CZ235193A3 (en) 1994-03-16
AU2026992A (en) 1992-12-30
NZ242724A (en) 1994-09-27
EP0584250A4 (enExample) 1994-03-30
ZA923557B (en) 1993-11-15
IE921534A1 (en) 1992-11-18
JPH06508128A (ja) 1994-09-14

Similar Documents

Publication Publication Date Title
MX9202243A (es) Composicion farmaceutica de antagonista del receptor de angiotensina ii y bloqueadores del canal de calcio.
BR9206722A (pt) Antagonista receptores de endotelina
IL99246A0 (en) Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
FI935175L (fi) Tyrosinkinas- HER4-humanreceptor
DK0938318T3 (da) Tablet med kontrolleret frigivelse af alfuzosinchlorhydrat
ATE397459T1 (de) Sofort auflösbare medizinische zusammenstellung
FI941178L (fi) 5-HT4-reseptoriantagonisteja
FI922143A7 (fi) Muscarinreceptorantagonister.
NO924775D0 (no) Substituerte benzimidazoler, fremgangsmaate for deres fremstilling og deres farmasoeytiske anvendelse
ITSV970008V0 (it) Apparecchio ortodontico per l'espansione e la contrazione ortodontica e ortopedica del mascellare superiore.
FI914262A7 (fi) 3-aryyli-4(3H)kinatsolinoni-CCK-antagonisteja ja niiden farmaseuttisiaformulaatioita
DE69429861D1 (de) Endothelin-rezeptor-antagonisten
MA22288A1 (fr) Compositions de shampooings doux
FR2675372B1 (fr) Prothese ossiculaire auto-ajustable de l'oreille moyenne.
FI914855L (fi) Ekstrudoitavan eteeni-hydroksiakrylaatti-sekapolymeerin käyttö
IT1301451B1 (it) Copolimeri del clorotrifluoroetilene
IS4597A (is) Ný lyfjafræðileg notkun AII-viðtaka mótlyfja
FI920190A7 (fi) Päällevalettava valmiste matolääkkeiden antamiseksi
DE69604968D1 (de) Wagenblockierkeil
BR9609914A (pt) Antagonista do receptor de endotelina
EP0914611A4 (en) TRANSACTIVATION OF LEPTIN
IT1283608B1 (it) Composizione farmaceutica per la terapia orale diuretica ed antiipertensiva.
DE69227940D1 (de) Menschlicher Neurokinin-1-Rezeptor
FI922346A7 (fi) Muscarinreceptorantagonister.
BR9006118A (pt) Monitor de canal multiplex